Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes - PubMed (original) (raw)
Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes
L Biancone et al. J Exp Med. 1996.
Abstract
CD5 is a 67-kD glycoprotein that is expressed on most T lymphocytes and on a subset of mature B cells. Although its physiologic function is unknown, several lines of evidence suggest that CD5 may play a role in the regulation of T cell activation and in T cell-antigen presenting cell interactions. Using a CD5-immunoglobulin fusion protein (CD5Rg, for receptorglobulin) we have uncovered a new CD5 ligand (CD5L) expressed on the surface of activated splenocytes. Stimulation of murine splenocytes with anti-CD3 and anti-CD28 antibodies induce transient expression of CD5L on B lymphocytes that lasts for approximately 72 h. Binding of CD5Rg to activated splenocytes is trypsin resistant and independent of divalent cations. However, it is pronase sensitive and dependent on N-linked glycosylation of CD5, since treatment of CD5Rg with PNGaseF on N-glycanase completely abrogates its ability to bind activated splenocytes. It addition to splenocytes, CD5L is expressed on activated murine T cell clones. Immunoprecipitation, antibody, and recombinant protein blocking studies indicate that CD5L is distinct from CD72, which has been proposed to be a CD5 ligand. To determine whether CD5-CD5L interaction might play a role in vivo, we tested the effect of CD5Rg in a murine model of antibody-mediated membranous glomerulonephritis. Injection of CD5Rg was found to abrogate development of the disease. Taken together, our results help identify a novel ligand of CD5 and propose a role for CD5 in the regulation of immune responses.
Similar articles
- A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.
Bikah G, Lynd FM, Aruffo AA, Ledbetter JA, Bondada S. Bikah G, et al. Int Immunol. 1998 Aug;10(8):1185-96. doi: 10.1093/intimm/10.8.1185. Int Immunol. 1998. PMID: 9723705 - The identification and characterization of a ligand for bovine CD5.
Haas KM, Estes DM. Haas KM, et al. J Immunol. 2001 Mar 1;166(5):3158-66. doi: 10.4049/jimmunol.166.5.3158. J Immunol. 2001. PMID: 11207268 - Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand.
Calvo J, Places L, Padilla O, Vilà JM, Vives J, Bowen MA, Lozano F. Calvo J, et al. Eur J Immunol. 1999 Jul;29(7):2119-29. doi: 10.1002/(SICI)1521-4141(199907)29:07<2119::AID-IMMU2119>3.0.CO;2-F. Eur J Immunol. 1999. PMID: 10427974 - CD5, an important regulator of lymphocyte selection and immune tolerance.
Raman C. Raman C. Immunol Res. 2002;26(1-3):255-63. doi: 10.1385/IR:26:1-3:255. Immunol Res. 2002. PMID: 12403363 Review. - Sympathetic nervous system--immune system interactions in young and old Fischer 344 rats.
Madden KS, Felten SY, Felten DL, Bellinger DL. Madden KS, et al. Ann N Y Acad Sci. 1995 Dec 29;771:523-34. doi: 10.1111/j.1749-6632.1995.tb44707.x. Ann N Y Acad Sci. 1995. PMID: 8597427 Review. No abstract available.
Cited by
- Interrogating ligand-receptor interactions using highly sensitive cellular biosensors.
Funk MA, Leitner J, Gerner MC, Hammerler JM, Salzer B, Lehner M, Battin C, Gumpelmair S, Stiasny K, Grabmeier-Pfistershammer K, Steinberger P. Funk MA, et al. Nat Commun. 2023 Nov 28;14(1):7804. doi: 10.1038/s41467-023-43589-1. Nat Commun. 2023. PMID: 38016944 Free PMC article. - CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.
He M, Roussak K, Ma F, Borcherding N, Garin V, White M, Schutt C, Jensen TI, Zhao Y, Iberg CA, Shah K, Bhatia H, Korenfeld D, Dinkel S, Gray J, Ulezko Antonova A, Ferris S, Donermeyer D, Lindestam Arlehamn C, Gubin MM, Luo J, Gorvel L, Pellegrini M, Sette A, Tung T, Bak R, Modlin RL, Fields RC, Schreiber RD, Allen PM, Klechevsky E. He M, et al. Science. 2023 Feb 17;379(6633):eabg2752. doi: 10.1126/science.abg2752. Epub 2023 Feb 17. Science. 2023. PMID: 36795805 Free PMC article. - Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease.
Casadó-Llombart S, Velasco-de Andrés M, Català C, Leyton-Pereira A, Gutiérrez-Cózar R, Suárez B, Armiger N, Carreras E, Esteller M, Ricart E, Ordás I, Gisbert JP, Chaparro M, Esteve M, Márquez L, Busquets D, Iglesias E, García-Planella E, Martín-Arranz MD, Lohmann J, Ayata CK, Niess JH, Engel P, Panés J, Salas A, Domènech E, Lozano F; ENEIDA Project of GETECCU. Casadó-Llombart S, et al. Front Immunol. 2022 Sep 21;13:966184. doi: 10.3389/fimmu.2022.966184. eCollection 2022. Front Immunol. 2022. PMID: 36211446 Free PMC article. - CD5 Controls Gut Immunity by Shaping the Cytokine Profile of Intestinal T Cells.
Schuster C, Kiaf B, Hatzihristidis T, Ruckdeschel A, Nieves-Bonilla J, Ishikawa Y, Zhao B, Zheng P, Love PE, Kissler S. Schuster C, et al. Front Immunol. 2022 Jun 2;13:906499. doi: 10.3389/fimmu.2022.906499. eCollection 2022. Front Immunol. 2022. PMID: 35720357 Free PMC article. - CD5 Deficiency Alters Helper T Cell Metabolic Function and Shifts the Systemic Metabolome.
Whitley KV, Freitas CMT, Moreno C, Haynie C, Bennett J, Hancock JC, Cox TD, Pickett BE, Weber KS. Whitley KV, et al. Biomedicines. 2022 Mar 18;10(3):704. doi: 10.3390/biomedicines10030704. Biomedicines. 2022. PMID: 35327505 Free PMC article.
References
- J Immunol. 1983 May;130(5):2033-7 - PubMed
- Science. 1995 Sep 1;269(5228):1273-8 - PubMed
- J Immunol. 1985 Oct;135(4):2331-6 - PubMed
- J Immunol. 1986 Mar 1;136(5):1734-7 - PubMed
- J Immunol. 1986 Sep 15;137(6):1793-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous